3Marcum Z A,Handler S M,Boyce R,et al.Medication misadventures in the elderly:a year in review[J].Am J Geriatr Pharmacother,2010,8(1):77-83.
4Zandieh S O,Goldmann D A,Keohane C A,et al.Risk factors in preventable adverse drug events in pediatric outpatients[J].J Pediatr,2008,152(2):225-231.
5Nuckols T K,Paddock S M,Bower A G,et al.Costs of intravenous adverse drug events in academic and nonacademic intensive care units[J].Med Care,2008,46(1):17-24.
4Kelly MS,Chad SJ,Byron Y,et al. Prevalence and characteristics of adverse drug reactions in neurosurgieal intensive care patients[J]. Neurosurgery, 2006, 58(3): 426
5Zandieh SO, Goldmann DA, Keohane CA, et al .Risk factors in preventable adverse drug events in pediatric outpatients[J ]. J Pediatr, 2008,152(2) : 225.
6Nuckols TK, Paddock SM, Bower AG, et al. Costs of intravenous adverse drug events in academic and nonacademic intensive care units[J] .Med Care, 2008, 46(1) : 17.
7Thomsen LA, Winterstein AG, Sφndergaard B, et al. Systematic review of the incidence and characteristics of preventable adverse drug events in ambulatory care [J ] . Ann Pharmacother ,2007,41(9) :1 411.
8杨宝峰主编.药理学[M].第6版.北京:人民卫生出版社,2007:28-29.
9Nuckols TK, Paddock SM, Bower AG, et al. Costs of intravenous adverse drug events in academic and nonacademic intensive care units[J]. Med Care, 2008, 46 (1) : 17.
